Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

BMC Cancer

Table 3 Association between MMP2 overexpression and survival in patients with breast cancer

Survival	Subgroup	No. of studies	No. of patients	I² (%)	P for heterogeneity	Pooled HR (95%CI)	P for effect size
DFS	Overall	3	240	0	0.724	1.79 (0.90–3.54)	0.096
OS	Overall	14	2128	30.6	0.131	1.60 (1.33–1.94)	< 0.001
	Ethnicity
	Caucasians	7	1100	0	0.569	2.21 (1.47–3.06)	< 0.001
	Asians	7	1028	47.5	0.075	1.75 (1.14–2.70)	0.011
	IHC analysis standard
	Percentage	7	1228	0	0.729	1.97 (1.46–2.68)	< 0.001
	SI	7	900	53.2	0.046	1.87 (1.08–3.26)	0.026
	HR data
	Reported	9	1706	51.5	0.036	1.95 (1.37–2.79)	< 0.001
	Estimated	5	422	0	0.641	1.90 (0.89–4.07)	0.097
	Analysis model
	Univariate	9	1245	32.2	0.160	1.52 (1.19–1.94)	0.001
	Multivariate	6	1153	29.9	0.211	1.78 (1.33–2.39)	< 0.001
	Sample size
	> 150	5	796	23.3	0.266	1.43 (1.15–1.78)	0.002
	≤150	9	1332	20.2	0.263	2.19 (1.53–3.13)	< 0.001
	Cancer subtype
	IDC	4	621	48.0	0.123	1.35 (1.06–1.73)	0.017
RFS	Overall	5	712	0	0.892	1.21 (0.82–1.81)	0.338

OS overall survival, DFS disease-free survival, RFS recurrence-free survival, IHC immunohistochemistry, IDC infiltrating ductal carcinoma, SI staining index, HR hazard ratio

ISSN: 1471-2407